Chronic myeloid leukemia

Journal of Association of Physicians of India

Volumn 52, Issue MAY, 2004, Pages 410-416

  Singhal, N ^a   Bapsy, P P ^a   Babu, K G ^a   George, J ^a  

^a KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; HYDROXYUREA; IMATINIB; INTERFERON; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

CHRONIC MYELOID LEUKEMIA; HUMAN; METHODOLOGY; REVIEW; STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC AGENTS; BUSULFAN; HUMANS; HYDROXYUREA; INTERFERONS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PYRIMIDINES; STEM CELL TRANSPLANTATION;

EID: 13944265649     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Kumar L, Sagar TG, Maitreyan V, Maghi U, Shanta V. Chronic granulocytic leukemia. A study of 160 cases. JAPI 1990;38:199-202.
2. Mauro MJ, O'Dwyer M, Heinrich MC, Druker BJ. STI 571: A paradigm of new agents for cancer therapeutics. J Clin Oncol 2002;20:325-334.
3. Horowitz MM, Rowling PA, Passweg JR. Allogeneic BMT for chronic myeloid leukemia - a report from IBMTR. Bone Marrow Transplant 1996;17(Suppl 3): S5-6.
4. Tomas JF, Lopez-Lorenzo JL, Requena MJ, Aguilar R, Steegman JL, Camara R, et al. Absence of influence of prior treatment with interferon on the outcome of allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone marrow transplant 1998;22:47-52.
5. Goldman JM, Szydlo R, Horowitz MM, Gale RP, Ash RC, Atkinson K, et al. Choice of a pretransplant treatment and timing of transplant for chronic myeloid leukemia in chronic phase. Blood 1993;82:2235-38.
6. Chao NJ, Schimdt GM, Niland JC, Amylon MD, Dagis AC, Long GD, et al. Cyclosporine, methotrexate and prednisone for prophylaxis of acute GVHD. NEJM 1993;329:1225-30.
7. Goldman JM, Gale RP, Horowitz MM. Bone Marrow Transplant for chronic myeloid leukemia in chronic phase: increased risk of relapse associated with T cell depletion. Annals of Internal Medicine 1988;108:806-14.
8. Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chaincey TR, Cliff RA et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. NEJM 1998;338:962-8.
9. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carrera Se, Devergie A et al. Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation. Lancet 1998;35:1087-92.
10. Dazzi F, Szydlo RM, Craddock C, Cross NCP, Kaeda J, Chase A, et al. Comparison of single dose and escalating dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000;95:67-71.
11. Goldman JM. Stem cell transplant for chronic myeloid leukemia: Its place in treatment algorithm - 2001. ASH educational book 2001;103-112.
12. Sokal JE, Cox EB, Baccarni M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in "Good Risk" chronic granulocytic leukemia. Blood 1984;63:789-99.
13. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alpha. J Nat Cancer Inst 1998;90:850-8.
14. CML trialists' collaborative Group. Interferon alpha versus chemotherapy for chronic myeloid leukemia: a meta analysis of seven randomized trials. J Nat Cancer Inst 1997; 89:1616-20.
15. Guilhot F, Chatang C, Michallet M, Guerci A, Horousseau JL, Maloisel F, et al. Interferon (-2b combined with cytarabine versus interferon alone in chronic myeloid leukemia. NEJM 1997;337:223-29.
16. Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C, et al. An evidence based analysis of the effect of Busulfan, Hydroxyurea, Interferon and Allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for American Society of Hematology. Blood 1999;94:1517-36.
17. Talpaz M, O' Brien S, Rose E, Gupta S, Shan J, Cortes J, et al. Phase I study of polyethylene glycol formulation of IFN in Philadelphia positive chronic myeloid leukemia. Blood 2001;98:1708-13.
18. Lipton JH, Khoroshko ND, Golenkow AK, Abdulkadyrov KM, Nair MK, Raghunadha Rao D, et al. A randomized multicentric comparative study of PEG-interferon (40kd) versus interferon in patients with treatment naïve chronic phase chronic myeloid leukemia. Blood 2002;100:782a.
19. Savage DG, Antman KH. Imatinib mesylate - A new oral targeted therapy. NEJM 2002;346(9):683-91.
20. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia. NEJM 2001;344:1031-7.
21. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Passerini CG, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. NEJM 2002;346:645-52.
22. Talpaz M, Silver RT, Druker BJ, Goldman JM, Passerini CG, Guilhot F, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase II study. Blood 2002;99:1928 -37.
23. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99:3530 -39.
24. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. NEJM 2003;348:994-1004.
25. Deininger MWN, O'Brien SG, Ford JM, Druker JB. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003;21:1637-47.
26. Hochhaus A, Kriel S, Corbin AS, La Rosce P, Muller MC, Lahaye T, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI 571) therapy. Leukemia 2002;16:2190-96.
27. Nimmanapalli R, Bhalla K. Mechanisms of resistance of imatinib mesylate in bcr-abl positive leukemia. Curr Opin Oncol 2002;14:616-20.
28. Rosti G, Trabacchi E, Bassi S, Bonifazi F, de Vivo A, Martinelli G, et al. Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia. Hematologica 2003;88:256-59.